Oral and radiological features of mucormycosis in post-Covid patients – a clinical study

Introduction. Mucormycosis, commonly referred to as “black fungus,” has emerged as a life-threatening opportunistic infection, particularly in post-COVID patients. This study aims to evaluate the clinical, radiological, and treatment-related features of mucormycosis in post-COVID patients and assess...

Full description

Saved in:
Bibliographic Details
Main Authors: Nitish Kumar Kompalli, Rohit Kumar Kompalli, Soumya Athota
Format: Article
Language:English
Published: Amaltea Medical Publishing House 2024-09-01
Series:Romanian Journal of Infectious Diseases
Subjects:
Online Access:https://rjid.com.ro/articles/2024.3/RJID_2024_3_Art-11.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850231228249145344
author Nitish Kumar Kompalli
Rohit Kumar Kompalli
Soumya Athota
author_facet Nitish Kumar Kompalli
Rohit Kumar Kompalli
Soumya Athota
author_sort Nitish Kumar Kompalli
collection DOAJ
description Introduction. Mucormycosis, commonly referred to as “black fungus,” has emerged as a life-threatening opportunistic infection, particularly in post-COVID patients. This study aims to evaluate the clinical, radiological, and treatment-related features of mucormycosis in post-COVID patients and assess their outcomes. Materials and methods. This observational clinical study was conducted from April 2021 to October 2021, involving 50 consecutive post-COVID patients who presented with clinical and radiological features of mucormycosis. Demographic data, clinical symptoms, comorbidities, laboratory investigations, radiological findings, and treatment details were collected. Patients underwent computed tomography (CT) to assess bone involvement, sinus, and orbital involvement. Treatment regimens, including antifungal therapy and surgical interventions, were recorded. Patients were followed up for recurrence and long-term outcomes. Results. The majority of the patients were males (58%) and in the 31-45 age group (34%). Diabetes mellitus (60%) and steroid use (80%) were the most common comorbidities. Clinically, 70% of patients presented with soft tissue swelling or necrosis, and 44% had black eschar on the palate. CT findings revealed maxillary bone involvement in 56% of cases and sinus involvement in 50%. Orbital involvement was noted in 20%. Amphotericin B was the most commonly used antifungal therapy (70%), and 60% of patients underwent debridement. The overall recovery rate was 70%, with a recurrence rate of 16%. Facial deformities or ongoing oral issues were noted in 24% of patients during follow-up. Conclusion. Mucormycosis in post-COVID patients is associated with high morbidity, particularly in those with diabetes and those treated with corticosteroids. Antifungal therapy combined with surgical intervention yielded a 70% recovery rate, although recurrence and long-term complications were observed. Early diagnosis, appropriate antifungal therapy, and aggressive surgical management are critical to improving outcomes. Preventive strategies, including better management of comorbidities and judicious use of steroids, are essential in reducing the burden of mucormycosis in post-COVID patients.
format Article
id doaj-art-daebaa3d2fee4c38828810b5975591a5
institution OA Journals
issn 1454-3389
2069-6051
language English
publishDate 2024-09-01
publisher Amaltea Medical Publishing House
record_format Article
series Romanian Journal of Infectious Diseases
spelling doaj-art-daebaa3d2fee4c38828810b5975591a52025-08-20T02:03:36ZengAmaltea Medical Publishing HouseRomanian Journal of Infectious Diseases1454-33892069-60512024-09-0127323023610.37897/RJID.2024.3.11Oral and radiological features of mucormycosis in post-Covid patients – a clinical studyNitish Kumar Kompalli0Rohit Kumar Kompalli1Soumya Athota2Kotilingams Dental Clinic, Kothapet, Guntur, Andhra Pradesh, IndiaKamineni Institute of Medical Sciences, Narketpally, Telangana, IndiaSri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, IndiaIntroduction. Mucormycosis, commonly referred to as “black fungus,” has emerged as a life-threatening opportunistic infection, particularly in post-COVID patients. This study aims to evaluate the clinical, radiological, and treatment-related features of mucormycosis in post-COVID patients and assess their outcomes. Materials and methods. This observational clinical study was conducted from April 2021 to October 2021, involving 50 consecutive post-COVID patients who presented with clinical and radiological features of mucormycosis. Demographic data, clinical symptoms, comorbidities, laboratory investigations, radiological findings, and treatment details were collected. Patients underwent computed tomography (CT) to assess bone involvement, sinus, and orbital involvement. Treatment regimens, including antifungal therapy and surgical interventions, were recorded. Patients were followed up for recurrence and long-term outcomes. Results. The majority of the patients were males (58%) and in the 31-45 age group (34%). Diabetes mellitus (60%) and steroid use (80%) were the most common comorbidities. Clinically, 70% of patients presented with soft tissue swelling or necrosis, and 44% had black eschar on the palate. CT findings revealed maxillary bone involvement in 56% of cases and sinus involvement in 50%. Orbital involvement was noted in 20%. Amphotericin B was the most commonly used antifungal therapy (70%), and 60% of patients underwent debridement. The overall recovery rate was 70%, with a recurrence rate of 16%. Facial deformities or ongoing oral issues were noted in 24% of patients during follow-up. Conclusion. Mucormycosis in post-COVID patients is associated with high morbidity, particularly in those with diabetes and those treated with corticosteroids. Antifungal therapy combined with surgical intervention yielded a 70% recovery rate, although recurrence and long-term complications were observed. Early diagnosis, appropriate antifungal therapy, and aggressive surgical management are critical to improving outcomes. Preventive strategies, including better management of comorbidities and judicious use of steroids, are essential in reducing the burden of mucormycosis in post-COVID patients.https://rjid.com.ro/articles/2024.3/RJID_2024_3_Art-11.pdfmucormycosispost-covidantifungal therapydiabetes mellitusradiological findingsorbital involvementsteroid therapy
spellingShingle Nitish Kumar Kompalli
Rohit Kumar Kompalli
Soumya Athota
Oral and radiological features of mucormycosis in post-Covid patients – a clinical study
Romanian Journal of Infectious Diseases
mucormycosis
post-covid
antifungal therapy
diabetes mellitus
radiological findings
orbital involvement
steroid therapy
title Oral and radiological features of mucormycosis in post-Covid patients – a clinical study
title_full Oral and radiological features of mucormycosis in post-Covid patients – a clinical study
title_fullStr Oral and radiological features of mucormycosis in post-Covid patients – a clinical study
title_full_unstemmed Oral and radiological features of mucormycosis in post-Covid patients – a clinical study
title_short Oral and radiological features of mucormycosis in post-Covid patients – a clinical study
title_sort oral and radiological features of mucormycosis in post covid patients a clinical study
topic mucormycosis
post-covid
antifungal therapy
diabetes mellitus
radiological findings
orbital involvement
steroid therapy
url https://rjid.com.ro/articles/2024.3/RJID_2024_3_Art-11.pdf
work_keys_str_mv AT nitishkumarkompalli oralandradiologicalfeaturesofmucormycosisinpostcovidpatientsaclinicalstudy
AT rohitkumarkompalli oralandradiologicalfeaturesofmucormycosisinpostcovidpatientsaclinicalstudy
AT soumyaathota oralandradiologicalfeaturesofmucormycosisinpostcovidpatientsaclinicalstudy